Moreover, several ICIs, including pembrolizumab, nivolumab, and atezolizumab, have been approved as subsequent therapies for patients with advanced or metastatic NSCLC if they have not yet received a PD-1/PD-L1 inhibitor. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.